{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-060366","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.417176+00:00","generated_at":"2026-05-18T10:33:48.761021+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic","bullets":["IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.","Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.","Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.","Applications pending in US, Canada, Japan, China, and India."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-060366","json":"https://secwatch.observer/filing/0001213900-25-060366.json","markdown":"https://secwatch.observer/filing/0001213900-25-060366.md","text":"https://secwatch.observer/filing/0001213900-25-060366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/0001213900-25-060366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025060366/ea0247668-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:33:48.761021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}